From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.
The experts
Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.